FOLD News Alert Amicus Therapeutics (FOLD) 8.88 01/12/2015 1

New Post Public Reply Private Reply Replies (0) Message Board

Jan 12, 2015 at 5:10 PM

Amicus Therapeutics (FOLD) 8.88 $FOLD

Amicus provides 2015 outlook
Seeking Alpha - at Seeking Alpha - 2 hrs 38 mins ago

FOLD: 8.88 (+0.04)

Amicus Therapeutics Provides Full-Year 2015 Strategic Outlook and Financial Guidance
GlobeNewswire - Mon Jan 12, 6:30AM CST
MAA Submission for Migalastat Monotherapy for Fabry Disease on Track for Mid-2015
FOLD: 8.88 (+0.04)

Amicus Therapeutics (FOLD) Weak On High Volume
at The Street - Fri Jan 09, 9:03AM CST
Trade-Ideas LLC identified Amicus Therapeutics (FOLD) as a weak on high relative volume candidate
FOLD: 8.88 (+0.04)

Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1
at The Street - Thu Jan 08, 12:09PM CST
The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.
OREX: 5.75 (-0.03), BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), ESRX: 83.08 (-1.82), ACAD: 34.25 (+0.88), PCYC: 123.71 (-0.49), GILD: 101.21 (-1.00), NPSP: 45.35 (+3.44), SNY: 44.92 (+0.37), FOLD: 8.88 (+0.04), CELG: 117.00 (+3.33)

Migalstat HCL has positive impact on cardiac endpoint in Fabry study
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 10:31AM CST

FOLD: 8.88 (+0.04)

41.4% Return Seen to Date on SmarTrend Amicus Therapeutics Call (FOLD)
Comtex SmarTrend(R) - Thu Jan 08, 9:09AM CST
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on November 17th, 2014 at $6.66. In approximately 2 months, Amicus Therapeutics has returned 41.44% as of today's recent price of $9.42.
FOLD: 8.88 (+0.04)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:15AM CST

NRX: 7.90 (-1.19), BIND: 6.76 (-0.45), NBG: 1.66 (+0.09), MBT: 7.95 (-0.16), STML: 16.33 (+0.52), BIOD: 1.55 (-0.03), SIG: 124.42 (-0.50), PBR: 6.57 (-0.49), NBIX: 29.51 (+1.22), PIR: 16.75 (-0.01), VLCCF: 5.08 (+0.49), CONN: 18.28 (+0.22), CYTR: 3.44 (-0.14), PLX: 2.34 (+0.05), MEET: 1.43 (+0.01), INFI: 15.15 (+0.38), CYRN: 2.09 (+0.07), APOL: 26.05 (-0.89), CJJD: 3.16 (+0.39), CRK: 5.15 (-0.51), FOLD: 8.88 (+0.04), GST: 2.21 (-0.17)

Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac Endpoints From Fabry Monotherapy Study 011 and Long Term Extension Study
GlobeNewswire - Thu Jan 08, 6:41AM CST
Statistically Significant Improvements in Key Cardiac Parameter in Fabry Patients Previously Naïve to Therapy
FOLD: 8.88 (+0.04)

Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
at The Street - Tue Jan 06, 7:25PM CST
The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.
TSLA: 202.21 (-4.45), GE: 23.98 (-0.05), OVAS: 49.24 (-0.92), NMM: 12.41 (+0.12), XOM: 90.33 (-1.77), T: 33.49 (+0.09), ESPR: 48.52 (+3.58), IBM: 156.44 (-2.67), IRE: 14.01 (-0.12), DTV: 84.72 (-0.66), PTCT: 53.70 (+0.08), RCPT: 120.88 (-3.63), TEG: 77.50 (-0.53), PPG: 226.25 (-0.72), WAG: 76.05 (-0.49), BLUE: 101.95 (-1.68), TGTX: 15.98 (-0.88), WFC: 52.05 (-0.63), BA: 130.87 (-0.67), RAD: 7.79 (-0.04), ISIS: 73.34 (+1.08), RNA: 18.77 (+0.01), ACHN: 14.64 (+0.08), JCP: 8.14 (+0.23), CVS: 97.20 (-0.72), MCD: 93.01 (-0.20), AGIO: 131.55 (+3.43), CVX: 105.88 (-2.33), VZ: 47.08 (+0.32), FOLD: 8.88 (+0.04)

3 Biotech Stocks We're Watching Closest Ahead of the JPMorgan Healthcare Conference
Motley Fool Staff - Motley Fool - Mon Jan 05, 6:52AM CST
Source: GlaxoSmithKline via Flickr. When it comes to healthcare events, there is none more important than the JPMorgan Healthcare Conference. Filled with dozens upon dozens of biotech and medical device companies, the JPMorgan Healthcare...
JPM: 58.83 (-0.51), ICPT: 146.18 (-3.82), GSK: 42.93 (+0.13), FOLD: 8.88 (+0.04), CELG: 117.00 (+3.33)

24.9% Return Seen to Date on SmarTrend Amicus Therapeutics Call (FOLD)
Comtex SmarTrend(R) - Wed Dec 31, 5:00PM CST
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on November 17th, 2014 at $6.66. In approximately 1 month, Amicus Therapeutics has returned 24.92% as of today's recent price of $8.32.
FOLD: 8.88 (+0.04)

Use Options For A Chance To Buy FOLD At A 33% Discount
at The Street - Wed Dec 31, 10:47AM CST
Looking back to 43 days ago, Amicus Therapeutics Inc priced a 13,850,000 share secondary stock offering at $6.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the...
FOLD: 8.88 (+0.04)

Shares of FOLD Up 20.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 24, 11:12AM CST
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on November 17th, 2014 at $6.66. In approximately 1 month, Amicus Therapeutics has returned 20.57% as of today's recent price of $8.03.
FOLD: 8.88 (+0.04)

Amicus: Multiple Catalysts For Promising Fabry Treatment
Value Insight - at Seeking Alpha - Wed Dec 24, 11:01AM CST

FOLD: 8.88 (+0.04)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 4:35PM CST

AG: 6.78 (+0.54), CAMP: 17.36 (-0.08), AU: 10.77 (+0.63), UWTI: 2.95 (-0.51), ONTX: 4.23 (-0.14), NQ: 4.38 (-0.07), TPLM: 4.53 (-0.02), EPE: 8.78 (-0.40), GSAT: 2.72 (+0.03), FOLD: 8.88 (+0.04)

Amicus Therapeutics Added to NASDAQ Biotechnology Index (NBI)
GlobeNewswire - Mon Dec 22, 6:38AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that the Company was added to the NASDAQ Biotechnology Index (Nasdaq:NBI) (Nasdaq:XNBI), effective prior to the market open on December 22, 2014.
FOLD: 8.88 (+0.04)

Amicus Therapeutics to Present Program Updates at 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Dec 22, 6:30AM CST
New Cardiac Data from Migalastat Monotherapy Phase 3 Study 011 for Fabry Disease
JPM: 58.83 (-0.51), FOLD: 8.88 (+0.04)

Shares of FOLD Up 16.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 17, 9:51AM CST
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on November 17th, 2014 at $6.66. In approximately 1 month, Amicus Therapeutics has returned 16.07% as of today's recent price of $7.73.
FOLD: 8.88 (+0.04)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 39.27 (-3.99), ZSPH: 40.88 (-0.14), AMRN: 1.06 (-0.02), OPHT: 51.28 (+0.35), AERI: 29.51 (-0.58), ASPX: 59.91 (+0.57), CNCE: 13.53 (-0.20), ICEL: 5.52 (-0.15), GWPH: 78.73 (+0.20), AUXL: 36.44 (-0.07), RTRX: 13.52 (-0.09), RCPT: 120.88 (-3.63), AAVL: 58.85 (+0.19), AKBA: 11.43 (-0.07), EXPR: 14.57 (+0.45), RARE: 55.81 (+1.75), RLYP: 33.57 (+0.84), PETX: 18.67 (+0.07), ENTA: 49.41 (-0.70), RDUS: 38.90 (-2.02), CARA: 10.99 (+0.04), FLML: 18.23 (-0.03), ALIM: 5.66 (-0.07), ANIP: 55.88 (-0.07), ICPT: 146.18 (-3.82), RVNC: 17.05 (-0.10), POZN: 6.94 (-0.85), FPRX: 28.00 (+3.09), ZFGN: 37.55 (-2.01), CRIS: 1.40 (-0.01), QLTI: 4.49 (+0.10), PCYC: 123.71 (-0.49), PTX: 8.82 (+0.03), CLDN: 18.35 (-0.25), RIGL: 2.15 (-0.04), HPTX: 25.22 (+0.27), AMPH: 12.00 (+0.02), INO: 9.30 (-0.19), VSAR: 22.93 (-0.28), FMI: 46.74 (+22.81), TBPH: 16.84 (-0.58), XLRN: 40.89 (-0.25), MGNX: 33.87 (-0.04), INSM: 14.60 (-0.95), ONTX: 4.23 (-0.14), ALDR: 29.05 (+0.98), SAGE: 43.81 (-0.58), KITE: 82.35 (+3.21), CGEN: 9.26 (-0.03), FOLD: 8.88 (+0.04), KPTI: 29.90 (-2.14)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 39.27 (-3.99), ZSPH: 40.88 (-0.14), AMRN: 1.06 (-0.02), OPHT: 51.28 (+0.35), AERI: 29.51 (-0.58), ASPX: 59.91 (+0.57), CNCE: 13.53 (-0.20), ICEL: 5.52 (-0.15), GWPH: 78.73 (+0.20), AUXL: 36.44 (-0.07), RTRX: 13.52 (-0.09), RCPT: 120.88 (-3.63), AAVL: 58.85 (+0.19), AKBA: 11.43 (-0.07), EXPR: 14.57 (+0.45), RARE: 55.81 (+1.75), ZGNX: 1.38 (-0.07), RLYP: 33.57 (+0.84), PETX: 18.67 (+0.07), ENTA: 49.41 (-0.70), RDUS: 38.90 (-2.02), CARA: 10.99 (+0.04), FLML: 18.23 (-0.03), ALIM: 5.66 (-0.07), ANIP: 55.88 (-0.07), ICPT: 146.18 (-3.82), RVNC: 17.05 (-0.10), POZN: 6.94 (-0.85), NDAQ: 47.35 (-1.15), FPRX: 28.00 (+3.09), CRIS: 1.40 (-0.01), ZFGN: 37.55 (-2.01), QLTI: 4.49 (+0.10), PCYC: 123.71 (-0.49), PTX: 8.82 (+0.03), CLDN: 18.35 (-0.25), RIGL: 2.15 (-0.04), HPTX: 25.22 (+0.27), AMPH: 12.00 (+0.02), INO: 9.30 (-0.19), VSAR: 22.93 (-0.28), FMI: 46.74 (+22.81), TBPH: 16.84 (-0.58), XLRN: 40.89 (-0.25), MGNX: 33.87 (-0.04), INSM: 14.60 (-0.95), ONTX: 4.23 (-0.14), ALDR: 29.05 (+0.98), SAGE: 43.81 (-0.58), KITE: 82.35 (+3.21), CGEN: 9.26 (-0.03), FOLD: 8.88 (+0.04), KPTI: 29.90 (-2.14)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hot Chili Sizzles with La Verde Copper Drill Gains

Big Copper Moves at La Verde: What's New? Look, when it comes to copper, Hot Chili Limited is throwing down some serious markers. You see, their La Verde project is turning into a hotbed of activity thanks to their latest drilling revelations. They've managed to confirm a second porphyry center, which is like finding another gold mine, except with copper. This essentially...

Blue Moon Metals Scraps Major Acquisition Plan

Blue Moon Metals' Acquisition Detour Blue Moon Metals Inc. (NASDAQ: BMM), a name that's been stirring up chatter for its ambitious mining ventures, has waved goodbye to its planned acquisition of 33 U.S.-based tungsten and antimony projects. This move, announced on October 30, 2026, may have caught some investors off guard. The acquisition sounded like a good fit: a...

CMRE Facing Legal Heat Over Wage Allegations

Another Day, Another Lawsuit Ah, work. It’s what gets us up in the morning, whether we like it or not. Yet, for many, it can feel more like a dubious hustle when the rewards don't match the effort. Now, CMRE Financial Services, Inc. finds itself under the legal microscope, thanks to a fresh class-action lawsuit filed by the legal eagles at Blumenthal Nordrehaug Bhowmik...

Brewers '26 Win Fuels Cap Craze: New Era's Play

Brewers: Finally on Top of the World Boy oh boy, the Milwaukee Brewers have finally done it! After years of being the underdogs, the team has clinched their first-ever World Series championship in 2026. You think you're dreaming, but no, it's the real deal. The Brewers, once just a hopeful name on the roster of Major League Baseball's teams, have stormed their way to a...

Aemetis Faces Class Action Over Wage Violation Claims

California's Alert: Labor Code Violations Under Scrutiny Allegations like these can shake things up pretty quick, especially when you're dealing with harsh financial climates. Aemetis Advanced Fuel Keyes, Inc. is in hot water yet again—this time, they're being called out for allegedly messing up the wage game for their workers. That's right, a class action lawsuit filed...

UBCF Strikes Big in Times Square with New Billboards

From the Shadows to the Spotlight Ever seen someone step up to the plate and knock it out of the park? That's what the United Breast Cancer Foundation (UBCF) is doing by plastering their mission right across Times Square. Talk about grabbing the bull by the horns, eh? With not one, but two billboards now gracing one of the globe's most iconic public spaces, they've...

SCANOLOGY's AirGO Pad Revolutionizes On-Site Inspections

Mobile 3D Scanning — Finally, Some Real Innovation Gone are the days where engineers had to cart around bulky laptops just to finish a simple inspection. SCANOLOGY has thrown a real game-changer into the mix with their new AirGO Pad. It's essentially a slick tablet that keeps your scanning, inspecting, and reporting all in one place, right beside whatever tangled hunk...

HanAll F&B Pioneers New Path for Domestic Rice Noodles

New Spin on an Old Favorite: Rice Noodles Forget about the same old wheat noodles clogging up the pantry. HanAll F&B is revamping the noodle game with a homegrown twist, setting sights on a future where Korean rice isn't just for steaming, soup, or sushi. This outfit from Taebaek, Gangwon, has got its hands deep in the rice flour, finessing a patent that aims to make...

Zhimeng Biopharma Hits Key Milestone in ALS Drug Trial

Pivotal Point for Zhimeng's ALS Efforts Folks, get this—Zhimeng Biopharma's rolling out the big guns here with a significant step forward in their ALS treatment quest. This company just wrapped up patient enrollment for their next-gen ALS drug, CB03-154. We're talking about 255 patients now on board for a Phase 2/3 trial. The ground's shaking a bit because this...

PRTH Shareholder Concerns Amid Merger Investigation

Behind Closed Doors: PRTH's Merger Drama Unfolds The market's got its share of tricky maneuvers and right now, Priority Technology Holdings, Inc. (NASDAQ:PRTH) is under the magnifying glass. Levi & Korsinsky, LLP has kicked off an investigation into the nitty-gritty of PRTH's acquisition by its largest shareholder—none other than their own Chairman and CEO, Thomas C....